ライフサイエンスコーパス: inhalational anesthetic

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ures incompatible with effective delivery of inhalational anesthetics.

2 lar concentration is central to the study of inhalational anesthetics.

3 ose receptors is less certain in the case of inhalational anesthetics.

4 the PDZ domain as a new molecular target for inhalational anesthetics.

5 Administration of inhalational anesthetics.

6 We now report that inhalational anesthetics affect gene expression of nitri

7 advantages for any of the commonly available inhalational anesthetic agents and each can be used for

8 Inhalational anesthetic agents have also been shown to r

9 Xenon and dichloromethane are inhalational anesthetic agents whose binding to myoglobi

10 ative, analgesics, benzodiazepines, opioids, inhalational anesthetic agents, nitrous oxide, ketamine,

11 ous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse.

12 ersing the effects of some anesthetic drugs (inhalational anesthetics and muscle relaxants) are descr

13 This is a novel interaction between inhalational anesthetics and the NO signaling pathway an

14 Inhalational anesthetics are bronchodilators with immuno

15 They also received inhalational anesthetics because of refractory bronchoco

16 To identify inhalational anesthetic binding domains in a ligand-gate

17 To determine inhalational anesthetic binding domains on a ligand-gate

18 Postconditioning with inhalational anesthetics can reduce ischemia-reperfusion

19 At surgical depths of anesthesia, inhalational anesthetics cause a loss of motor response

20 These data indicate that inhalational anesthetics cause activation of RTN neurons

21 Currently, it is thought that inhalational anesthetics cause anesthesia by binding to

22 during surgery (derived from mean end-tidal inhalational anesthetic concentrations).

23 esthetized with a virtually nondefluorinated inhalational anesthetic (desflurane) or with a nonfluori

24 Inhalational anesthetic dose increase and reduced risk o

25 High inhalational anesthetic dose of 1.20 (1.13-1.30) (median

26 We sought to determine the effect of inhalational anesthetic dose on risk of severe postopera

27 Additionally, high inhalational anesthetic dose was associated with lower 3

28 e that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifical

29 Intraoperative use of higher inhalational anesthetic doses is strongly associated wit

30 Median effective dose equivalent of inhalational anesthetics during surgery (derived from me

31 can be utilized to probe the binding of the inhalational anesthetic halothane to an anesthetic-bindi

32 Clinical concentrations of the inhalational anesthetic, halothane (1 rat MAC, 1.2 vol.%

33 Inhalational anesthetics have been shown to inhibit the

34 sting differences in the binding domains for inhalational anesthetics in the nAChR.

35 amuscular sedative was given, followed by an inhalational anesthetic induction and mechanical ventila

36 sthesia is indicated for procedures in which inhalational anesthetics may not be safely or effectivel

37 w that clinically relevant concentrations of inhalational anesthetics modulate neuronal Ih and the co

38 A better understanding of the effect of inhalational anesthetics on fetal cardiac function and s

39 ulate based on these data that sedation with inhalational anesthetics outside of the operating room m

40 Isoflurane, the most widely used inhalational anesthetic, releases inorganic fluoride dur

41 The molecular pharmacology of inhalational anesthetics remains poorly understood.

42 iments were performed with the commonly used inhalational anesthetic sevoflurane.

43 in experimental traumatic brain injury with inhalational anesthetics, these results indicate that th

44 ectroscopic probe to study the binding of an inhalational anesthetic to a model membrane protein.

45 the native RTN current (i.e., suppression by inhalational anesthetics, weak rectification, inhibition

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。